> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Review Chiesi Cystic Fibrosis NDA
- URL: https://www.fdaweb.com/panel-to-review-chiesi-cystic-fibrosis-nda/
- Published: 2019-03-25T12:00:00.000Z
- Updated: 2026-09-15T01:15:31.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5143686

*Federal Register* notice: FDA has announced a 5/8 Pulmonary-Allergy Drugs Advisory Committee meeting. Panel members are scheduled to discuss a Chiesi USA NDA for mannitol inhalation powder, indicated for managing cystic fibrosis to improve pulmonary function in patients 18 years of age and older in conjunction with standard therapies. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2019-03-25/pdf/2019-05658.pdf?ref=fdaweb.com).